402:(Xolair). The Changs took it to the court in 1993 and accused Genentech of misappropriating its work, but the legal battle dragged on. Chang was granted patents in 1995. In 1996, Tanox and Genentech settled out of court, with Genentech paying Tanox a compensation. The two companies and Novartis agreed to jointly develop Xolair, under the reasoning that Genentech had better manufacturing processes to produce antibodies in large quantities. Chang not only proposed the theory behind anti-IgE therapeutics, but also actively participated in the phase I and II
1325:
1306:
435:
to the bank's claim for a sum of $ 1.7 million. While successful in his claim at the High Court, the decision was reversed on appeal, where the
Singapore Court of Appeal stated that he had the requisite knowledge of shares to not rely on the advice of the bank. He also had to repay a $ 1.7 million debt incurred from investment losses. This case has since become a point of authority in contract law.
1062:
434:
Chang tried his hand at investing, purchasing large quantities of derivatives under
Deutsche Bank's advice. Unfortunately, his scientific expertise did not translate into financial acumen, and as a result he lost $ 50 million in total. Chang initiated a counter-claim for the amount lost in response
314:
therapeutics in 1987. IgE plays a central role in the initiation of hypersensitivity reactions in the human body, and is responsible for allergic diseases that affect 20–40% of the population in developed countries. Originating from Chang's research, antibodies that target the IgE-mediated allergic
343:. In 1993, Chang's patent was granted for his discovery of CεmX, a unique region on human membrane-bound IgE (mIgE), leading to another therapeutic approach to treating IgE-mediated diseases. Apart from anti-IgE therapeutics, Chang also first proposed the concept and methodology of the
413:
for peanut allergy, and obtained very positive results. Genentech, however, sued Tanox, arguing that their contract in 1996 should prevent Tanox from developing any potential competitor drugs to Xolair. Again, the dispute rose to the court. Although Tanox won the consent in a
375:, Inc., where he served as Vice President of Research & Development (1986–1996) and director of the board from 1986 until Tanox was acquired by Genentech in 2007. In order to secure funding for a start-up company based on family funds, the Changs sought collaboration with
1323:, "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils", published 1995-06-27, assigned to Tanox Biosystems, Inc.
1538:
1429:
Racine-Poon, A.; Botta, L.; Chang, T.W. (1997). "Clinical efficacy of CGP 51901, an anti-IgE chimeric monoclonal antibody, in patients with allergic rhinitis: is it related to the extent of IgE suppression and pharmacokinetics".
269:. Chang's mother, Yeh Ting-mei (葉丁妹), was an elementary school teacher, who worked as a housewife after marriage to raise five children. Chang obtained a bachelor's degree (1970) and master's degree (1972) in chemistry at the
228:
in Taiwan and served as the Dean (1996–1999) of the
College of Life Sciences. Chang was appointed by the Taiwanese government as President of the Development Center for Biotechnology (DCB) in 2000, and served as a
1304:, "Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils", published 1995-06-06, assigned to Tanox Biosystems, Inc.
1546:
1060:, Chang, Tse Wen, "Newly identified human epsilon immunoglobulin peptides and related products", published 1993-12-28, assigned to Tanox Biosystems, Inc.
509:
Detection of antibodies to human T-cell lymphotropic virus-III (HTLV-III) with an immunoassay employing a recombinant
Escherichia coli-derived viral antigenic peptide
409:
Meanwhile, after the settlement in 1996, Tanox continued to develop
Talizumab, not for allergic asthma but for peanut allergy. In 2001–2003, Talizumab entered
1076:
Chan, Yueh-Hsuan; Lee, Yu-Tzu; Chou, Hung-Wen; Wu, Pheidias C.; Chen, Jiun-Bo; Li, Chau-Hong; Cheng, Tien-Tien; Chen, Nien-Yi; Lue, Ko-Haung (2014-05-01).
1744:
1374:"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics"
458:
445:
398:
A few years later, legal disputes arose as the Changs discovered that
Genentech launched its own anti-IgE program, developing what now became known as
315:
pathway have proven effective in the treatment of various allergic diseases. Among these anti-IgE drugs are: Omalizumab (Xolair), approved by the U.S.
1638:
748:
1272:
630:
565:
1709:
230:
379:
in 1989, sending data and samples of early anti-IgE antibody, but talks with
Genentech were unsuccessful. In 1990, Tanox partnered with
347:
in 1983. By aligning antibodies of distinct specificities in a matrix-like manner, scientists are able to detect and quantify multiple
184:, born August 25, 1947) is an immunology researcher, whose career spans across academia and industry. His early research involving the
1475:
1432:
770:
1372:
Corne, J.; Djukanovic, R.; Thomas, L.; Warner, J.; Botta, L.; Grandordy, B.; Gygax, D.; Heusser, C.; Patalano, F. (1997-03-01).
832:
1734:
1177:
1007:
1581:
Jayaraman, K. S.; Louët, Sabine; Powell, Kendall; Ransom, John; Sheridan, Cormac; Vastag, Brian; Waltz, Emily (2006-03-01).
1340:
522:
Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-medicated allergic diseases
1539:"Deutsche Bank AG v Chang Tse Wen and another appeal. [2013] SGCA 49. Civil Appeals Nos 164 of 2012 and 2 of 2013"
1714:
1078:"Developing an antibody targeting CϵmX of mIgE for the treatment of allergic and other IgE-mediated diseases (VAC6P.954)"
1724:
237:
from 2002 to 2006. From 2006 to 2016, he was tenured as
Distinguished Research Fellow at the Genomics Research Center,
600:
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells
1729:
1496:
1704:
873:"Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations"
701:"Tanox, Inc. – Company Profile, Information, Business Description, History, Background Information on Tanox, Inc"
651:
Chang, Tse Wen; Chen, Christina; Lin, Chien-Jen; Metz, Martin; Church, Martin K.; Maurer, Marcus (2015-02-01).
613:
Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations
482:
266:
167:
464:
320:
270:
225:
205:
128:
67:
418:, it lost the arbitration that followed, and the development of Talizumab for peanut allergy was suspended.
316:
1123:
Chang, T. W. (1983-12-16). "Binding of cells to matrixes of distinct antibodies coated on solid surface".
871:
Chu, Hsing-Mao; Wright, Jon; Chan, Yueh-Hsuan; Lin, Chien-Jen; Chang, Tse Wen; Lim, Carmay (2014-01-24).
454:'s shortlist of personalities who made the most significant contribution to biotech in the past 10 years.
500:
1280:
859:
653:"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria"
625:
584:
573:
560:
990:
Leung DY, Shanahan WR, Li XM, Sampson HA (2004). "New approaches for the treatment of anaphylaxis".
1250:
626:
The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
410:
1517:
1193:
1739:
726:
700:
547:
508:
507:
Chang TW, Kato I, McKinney S, Chanda P, Barone AD, Wong-Staal F, Gallo RC, and Chang NT, 1985, "
1719:
521:
415:
254:
55:
1659:
1560:
928:
617:
604:
539:
351:
in one simultaneous attempt. Thereafter, many other types of microarrays emerged, including
216:
therapies for the treatment of allergic diseases. After Tanox's tripartite partnership with
1699:
884:
552:
526:
513:
496:
Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?
451:
1077:
994:. Novartis Foundation Symposia. Vol. 257. pp. 248–60, discussion 260–4, 276–85.
8:
792:
344:
278:
93:
888:
1615:
1582:
1457:
1105:
682:
356:
282:
274:
262:
151:
72:
1445:
1406:
1373:
585:
Cumulative environmental changes, skewed antigen exposure, and the increase of allergy
1620:
1602:
1449:
1411:
1393:
1348:
1226:
1173:
1148:
1140:
1136:
1097:
1093:
1013:
1003:
969:
910:
902:
843:
674:
328:
1461:
1218:
1109:
686:
1610:
1594:
1441:
1401:
1385:
1132:
1089:
995:
959:
951:
892:
664:
599:
486:
311:
258:
250:
213:
185:
146:
88:
51:
1031:
1167:
595:
238:
137:
520:
Chang TW, Davis FM, Sun NC, Sun CRY, MacGlashan Jr. DW, and
Hamilton RG, 1990, "
265:, China. His father Chang Chun-an (張均安) spent his entire career working for the
669:
652:
403:
368:
352:
332:
234:
1476:"Genentech, Novartis and Tanox Settle Disputes Surrounding Xolair and TNX-901"
495:
380:
1693:
1606:
1397:
1352:
1230:
1144:
1101:
906:
612:
118:
999:
534:
200:), a medication that has been approved for the treatment of severe allergic
1624:
1057:
1017:
973:
914:
678:
290:
1453:
1415:
1320:
1301:
1152:
384:
1273:"Drug war. (small drug firm Tanox takes on Genentech over patent rights)"
964:
946:
336:
114:
1598:
814:
897:
872:
574:
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
468:
399:
193:
110:
1389:
392:
376:
324:
285:. Chang received his Ph.D. in 1977, and did postdoctoral research on
217:
388:
340:
221:
189:
533:
Peng C, Davis FM, Sun LK, Liou RS, Kim Y-W, and Chang TW, 1992, "
348:
1563:(in Chinese (Taiwan)). Genomics Research Center, Academia Sinica
611:
Chu HM, Wright J, Chan YH, Lin CJ, Chang TW & Lim C, 2014, "
339:, a high-affinity TNX-901 under active clinical development at
286:
201:
197:
175:
83:
624:
Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M, 2015, "
483:
Selection pressure of homologous proteins of varied activities
372:
209:
132:
947:"Effect of anti-IgE therapy in patients with peanut allergy"
820:. The Taiwan Society for Biochemistry and Molecular Biology.
1371:
446:
American
College of Allergy, Asthma, and Immunology (ACAAI)
1641:. The American Academy of Allergy, Asthma & Immunology
1580:
1166:
Abu-Jamous, Basel; Fa, Rui; Nandi, Asoke K. (2015-04-16).
224:
was forged in 1996, Chang returned to his alma mater, the
294:
1683:
945:
Leung DY, Sampson HA, Yunginger JW, et al. (2003).
426:
In 2014, Chang started the company Immunwork in Taiwan.
494:
Chang TW, Kung PC, Gingras SP, and Goldstein G, 1981, "
273:. Afterwards, Chang received a four-year fellowship at
989:
1428:
944:
561:
Anti-IgE as a mast cell-stabilizing therapeutic agent
459:
American Academy of Allergy, Asthma, and Immunology
1219:"How Genentech, Novartis Stifled A Promising Drug"
212:, a biopharmaceutical company specialized in anti-
1686:", Biotech company founded and directed by Chang.
1165:
751:. Board of Science and Technology, Executive Yuan
594:Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM,
1691:
870:
650:
985:
983:
940:
938:
319:(FDA) for the treatment of allergic asthma and
305:
192:-based therapeutics lead to the development of
1169:Integrative Cluster Analysis in Bioinformatics
631:The Journal of Allergy and Clinical Immunology
566:The Journal of Allergy and Clinical Immunology
257:, Taiwan in 1947. His ancestry traces back to
1075:
548:The pharmacological basis of anti-IgE therapy
327:(TNX-901), shown to be effective in treating
25:
980:
935:
773:. Genomics Research Center, Academia Sinica
1745:Taiwanese expatriates in the United States
657:Journal of Allergy and Clinical Immunology
1614:
1405:
1341:"Wrangling May Delay Peanut Allergy Drug"
963:
896:
668:
572:Chang TW, Wu PC, Hsu CL, Hung AF, 2007, "
535:A new isoform of human membrane-bound IgE
1433:Clinical Pharmacology & Therapeutics
1216:
475:
362:
1338:
1692:
1639:"Past AAAAI Honorary Award Recipients"
1270:
241:. He founded Immunwork, Inc. in 2014.
1378:The Journal of Clinical Investigation
1212:
1210:
1172:. John Wiley & Sons. p. 56.
1122:
1056:
429:
293:at the Center for Cancer Research at
1710:National Tsing Hua University alumni
438:
1660:"TWAS announces 2014 Prize winners"
1545:. 19 September 2013. Archived from
323:(primarily an autoimmune disease);
13:
1207:
281:in the muscle during fasting with
277:, where he did thesis research on
16:Taiwanese immunologist (born 1947)
14:
1756:
1676:
1217:Hamilton, David P. (2005-04-05).
931:. Drugdevelopment-technology.com.
830:
812:
1125:Journal of Immunological Methods
1094:10.4049/jimmunol.192.Supp.140.15
406:of Talizumab from 1990 to 1996.
1652:
1631:
1574:
1553:
1531:
1510:
1497:"Five Questions with Immunwork"
1489:
1468:
1422:
1365:
1332:
1313:
1294:
1271:Thorpe, Helen (April 1, 1995).
1264:
1243:
1186:
1159:
1116:
1069:
1050:
1024:
921:
729:. National Tsing Hua University
559:Chang TW and Shiung YY, 2006, "
444:Honorary Fellow Award from the
1339:Pollack, Andrew (2003-03-13).
864:
824:
806:
785:
763:
741:
719:
693:
644:
180:
171:
26:
1:
1499:(Blog). Terrapinn. 2016-09-23
1446:10.1016/S0009-9236(97)90087-4
929:"Xolair – Biological Therapy"
638:
465:The World Academy of Sciences
421:
321:chronic spontaneous urticaria
271:National Tsing Hua University
249:Chang was born and raised in
226:National Tsing Hua University
206:chronic spontaneous urticaria
129:National Tsing Hua University
68:National Tsing Hua University
1735:People from Zhongli District
1137:10.1016/0022-1759(83)90318-6
583:Chang TW and Pan AY, 2008, "
317:Food and Drug Administration
306:Contributions to biomedicine
244:
7:
1251:"Sample Business Contracts"
457:Honorary Fellow Award from
367:In March 1986, Tse Wen and
10:
1761:
1715:Taiwanese biotechnologists
1478:(Press release). Genentech
670:10.1016/j.jaci.2014.04.036
501:Proc. Natl. Acad. Sci. USA
471:in Medical Sciences, 2014.
208:. Chang is a cofounder of
1725:Harvard University alumni
1082:The Journal of Immunology
749:"張子文 (Dr. Tse-Wen Chang)"
481:Chang TW, Tang N, 1972, "
391:) and started developing
383:(which later merged with
300:
157:
145:
124:
106:
99:
79:
63:
34:
21:
1730:People from Taoyuan City
1088:(1 Supplement): 140.15.
831:龐, 中培 (September 2005).
411:phase II clinical trials
1705:Taiwanese immunologists
1000:10.1002/0470861193.ch20
289:immune mechanisms with
1583:"Who's who in biotech"
1253:. contracts.onecle.com
705:Reference for Business
589:Advances in Immunology
578:Advances in Immunology
416:federal district court
267:Taiwan Railroad Bureau
231:Science and Technology
1321:U.S. Patent 5428133 A
1302:U.S. Patent 5422258 A
1058:U.S. Patent 5274075 A
877:Nature Communications
634:, 135(2), 337–342.e2.
618:Nature Communications
605:Journal of Immunology
540:Journal of Immunology
476:Selected publications
363:Work in biotechnology
1587:Nature Biotechnology
1561:"Chang, Tse Wen 張子文"
965:10.1056/NEJMoa022613
813:張, 子文 (2017-03-23).
795:. Harvard University
608:, 184(4), 1748–1756.
569:, 117(6), 1203–1212.
553:Nature Biotechnology
527:Nature Biotechnology
514:Nature Biotechnology
452:Nature Biotechnology
310:Chang invented anti-
1599:10.1038/nbt0306-291
1543:www.singaporelaw.sg
1283:on October 29, 2013
1223:Wall Street Journal
889:2014NatCo...5.3139C
840:Scientific American
598:, Chang TW, 2010, "
357:protein microarrays
297:from 1977 to 1980.
279:protein degradation
94:Antibody microarray
1549:on 14 August 2018.
1345:The New York Times
898:10.1038/ncomms4139
833:"從抗體到藥物──專訪 張子文教授"
815:"走上新藥研究與事業新創的心路歷程"
430:Investing attempts
283:Alfred L. Goldberg
275:Harvard University
263:Guangdong Province
188:(IgE) pathway and
152:Alfred L. Goldberg
73:Harvard University
1390:10.1172/JCI119252
1179:978-1-118-90655-2
1009:978-0-470-86119-6
793:"Alfred Goldberg"
663:(2): 337–342.e2.
556:, 18(2), 157–162.
546:Chang TW, 2000, "
439:Awards and honors
329:allergic rhinitis
161:
160:
101:Scientific career
1752:
1671:
1670:
1668:
1667:
1656:
1650:
1649:
1647:
1646:
1635:
1629:
1628:
1618:
1578:
1572:
1571:
1569:
1568:
1557:
1551:
1550:
1535:
1529:
1528:
1526:
1525:
1514:
1508:
1507:
1505:
1504:
1493:
1487:
1486:
1484:
1483:
1472:
1466:
1465:
1426:
1420:
1419:
1409:
1369:
1363:
1362:
1360:
1359:
1336:
1330:
1329:
1328:
1324:
1317:
1311:
1310:
1309:
1305:
1298:
1292:
1291:
1289:
1288:
1279:. Archived from
1268:
1262:
1261:
1259:
1258:
1247:
1241:
1240:
1238:
1237:
1214:
1205:
1204:
1202:
1201:
1190:
1184:
1183:
1163:
1157:
1156:
1131:(1–2): 217–223.
1120:
1114:
1113:
1073:
1067:
1066:
1065:
1061:
1054:
1048:
1047:
1045:
1043:
1028:
1022:
1021:
987:
978:
977:
967:
952:N. Engl. J. Med.
942:
933:
932:
925:
919:
918:
900:
868:
862:
858:
856:
854:
849:on July 15, 2020
848:
842:. Archived from
837:
828:
822:
821:
819:
810:
804:
803:
801:
800:
789:
783:
782:
780:
778:
771:"Chang, Tse Wen"
767:
761:
760:
758:
756:
745:
739:
738:
736:
734:
723:
717:
716:
714:
712:
697:
691:
690:
672:
648:
504:, 78, 1805–1808.
359:, among others.
331:(hay fever) and
251:Zhongli District
186:Immunoglobulin E
182:
173:
147:Doctoral advisor
52:Zhongli District
48:
44:
42:
29:
28:
19:
18:
1760:
1759:
1755:
1754:
1753:
1751:
1750:
1749:
1690:
1689:
1679:
1674:
1665:
1663:
1658:
1657:
1653:
1644:
1642:
1637:
1636:
1632:
1579:
1575:
1566:
1564:
1559:
1558:
1554:
1537:
1536:
1532:
1523:
1521:
1516:
1515:
1511:
1502:
1500:
1495:
1494:
1490:
1481:
1479:
1474:
1473:
1469:
1427:
1423:
1370:
1366:
1357:
1355:
1337:
1333:
1326:
1319:
1318:
1314:
1307:
1300:
1299:
1295:
1286:
1284:
1269:
1265:
1256:
1254:
1249:
1248:
1244:
1235:
1233:
1215:
1208:
1199:
1197:
1192:
1191:
1187:
1180:
1164:
1160:
1121:
1117:
1074:
1070:
1063:
1055:
1051:
1041:
1039:
1030:
1029:
1025:
1010:
988:
981:
943:
936:
927:
926:
922:
869:
865:
852:
850:
846:
835:
829:
825:
817:
811:
807:
798:
796:
791:
790:
786:
776:
774:
769:
768:
764:
754:
752:
747:
746:
742:
732:
730:
725:
724:
720:
710:
708:
699:
698:
694:
649:
645:
641:
543:, 148, 129–136.
478:
441:
432:
424:
404:clinical trials
365:
353:DNA microarrays
345:antibody matrix
308:
303:
247:
239:Academia Sinica
233:Advisor of the
196:(also known as
141:Immunwork, Inc.
140:
138:Academia Sinica
136:
131:
92:
86:
71:
59:
49:
46:
45:August 25, 1947
40:
38:
30:
24:
17:
12:
11:
5:
1758:
1748:
1747:
1742:
1740:TWAS laureates
1737:
1732:
1727:
1722:
1717:
1712:
1707:
1702:
1688:
1687:
1678:
1677:External links
1675:
1673:
1672:
1651:
1630:
1593:(3): 291–300.
1573:
1552:
1530:
1509:
1488:
1467:
1421:
1384:(5): 879–887.
1364:
1331:
1312:
1293:
1263:
1242:
1206:
1185:
1178:
1158:
1115:
1068:
1049:
1023:
1008:
979:
958:(11): 986–93.
934:
920:
863:
823:
805:
784:
762:
740:
718:
707:. Advameg, Inc
692:
642:
640:
637:
636:
635:
622:
609:
592:
581:
570:
557:
544:
531:
518:
505:
492:
477:
474:
473:
472:
462:
461:(AAAAI), 2007.
455:
449:
440:
437:
431:
428:
423:
420:
369:Nancy T. Chang
364:
361:
333:peanut allergy
307:
304:
302:
299:
255:Taoyuan County
246:
243:
235:Executive Yuan
159:
158:
155:
154:
149:
143:
142:
126:
122:
121:
108:
104:
103:
97:
96:
81:
80:Known for
77:
76:
65:
61:
60:
56:Taoyuan County
50:
36:
32:
31:
22:
15:
9:
6:
4:
3:
2:
1757:
1746:
1743:
1741:
1738:
1736:
1733:
1731:
1728:
1726:
1723:
1721:
1720:Living people
1718:
1716:
1713:
1711:
1708:
1706:
1703:
1701:
1698:
1697:
1695:
1685:
1681:
1680:
1661:
1655:
1640:
1634:
1626:
1622:
1617:
1612:
1608:
1604:
1600:
1596:
1592:
1588:
1584:
1577:
1562:
1556:
1548:
1544:
1540:
1534:
1519:
1513:
1498:
1492:
1477:
1471:
1463:
1459:
1455:
1451:
1447:
1443:
1440:(6): 675–90.
1439:
1435:
1434:
1425:
1417:
1413:
1408:
1403:
1399:
1395:
1391:
1387:
1383:
1379:
1375:
1368:
1354:
1350:
1346:
1342:
1335:
1322:
1316:
1303:
1297:
1282:
1278:
1277:Texas Monthly
1274:
1267:
1252:
1246:
1232:
1228:
1224:
1220:
1213:
1211:
1195:
1194:"Our Founder"
1189:
1181:
1175:
1171:
1170:
1162:
1154:
1150:
1146:
1142:
1138:
1134:
1130:
1126:
1119:
1111:
1107:
1103:
1099:
1095:
1091:
1087:
1083:
1079:
1072:
1059:
1053:
1038:. May 4, 2017
1037:
1033:
1032:"Ligelizumab"
1027:
1019:
1015:
1011:
1005:
1001:
997:
993:
986:
984:
975:
971:
966:
961:
957:
954:
953:
948:
941:
939:
930:
924:
916:
912:
908:
904:
899:
894:
890:
886:
882:
878:
874:
867:
861:
845:
841:
834:
827:
816:
809:
794:
788:
772:
766:
750:
744:
728:
727:"2008年：張子文校友"
722:
706:
702:
696:
688:
684:
680:
676:
671:
666:
662:
658:
654:
647:
643:
633:
632:
627:
623:
620:
619:
614:
610:
607:
606:
601:
597:
593:
590:
586:
582:
580:, 93, 63–119.
579:
575:
571:
568:
567:
562:
558:
555:
554:
549:
545:
542:
541:
536:
532:
530:, 8, 122–126.
529:
528:
523:
519:
517:, 3, 905–909.
516:
515:
510:
506:
503:
502:
497:
493:
490:
489:
484:
480:
479:
470:
466:
463:
460:
456:
453:
450:
447:
443:
442:
436:
427:
419:
417:
412:
407:
405:
401:
396:
394:
390:
386:
382:
378:
374:
370:
360:
358:
354:
350:
346:
342:
338:
334:
330:
326:
322:
318:
313:
298:
296:
292:
288:
284:
280:
276:
272:
268:
264:
260:
256:
252:
242:
240:
236:
232:
227:
223:
219:
215:
211:
207:
203:
199:
195:
191:
187:
183:
177:
169:
165:
164:Tse Wen Chang
156:
153:
150:
148:
144:
139:
134:
130:
127:
123:
120:
119:Biotechnology
116:
112:
109:
105:
102:
98:
95:
90:
85:
82:
78:
74:
69:
66:
62:
57:
53:
47:(age 77)
37:
33:
23:Tse Wen Chang
20:
1664:. Retrieved
1654:
1643:. Retrieved
1633:
1590:
1586:
1576:
1565:. Retrieved
1555:
1547:the original
1542:
1533:
1522:. Retrieved
1512:
1501:. Retrieved
1491:
1480:. Retrieved
1470:
1437:
1431:
1424:
1381:
1377:
1367:
1356:. Retrieved
1344:
1334:
1315:
1296:
1285:. Retrieved
1281:the original
1276:
1266:
1255:. Retrieved
1245:
1234:. Retrieved
1222:
1198:. Retrieved
1188:
1168:
1161:
1128:
1124:
1118:
1085:
1081:
1071:
1052:
1040:. Retrieved
1036:Adis Insight
1035:
1026:
991:
955:
950:
923:
880:
876:
866:
851:. Retrieved
844:the original
839:
826:
808:
797:. Retrieved
787:
775:. Retrieved
765:
753:. Retrieved
743:
731:. Retrieved
721:
709:. Retrieved
704:
695:
660:
656:
646:
629:
616:
603:
591:, 98, 39–83.
588:
577:
564:
551:
538:
525:
512:
499:
487:
433:
425:
408:
397:
366:
309:
291:Herman Eisen
248:
179:
163:
162:
125:Institutions
100:
1700:1947 births
1520:. Immunwork
1196:. Immunwork
992:Anaphylaxis
491:, 239, 207.
395:(TNX-901).
337:Ligelizumab
204:and severe
181:Zhāng Zǐwén
115:Biomedicine
1694:Categories
1666:2017-05-26
1645:2017-05-26
1567:2017-05-26
1524:2017-05-26
1518:"Overview"
1503:2017-05-26
1482:2017-06-15
1358:2017-05-26
1287:2017-06-15
1257:2017-05-16
1236:2017-05-16
1200:2017-05-16
799:2017-06-13
639:References
621:, 5, 3139.
422:Post-Tanox
400:Omalizumab
381:Ciba-Geigy
259:Mei County
194:omalizumab
111:Immunology
70:(B.S; M.S)
41:1947-08-25
1684:Immunwork
1607:1087-0156
1398:0021-9738
1353:0362-4331
1231:0099-9660
1145:0022-1759
1102:0022-1767
907:2041-1723
393:Talizumab
377:Genentech
325:Talizumab
245:Education
218:Genentech
64:Education
1625:16525392
1462:28652703
1110:82305273
1018:15025403
974:12637608
915:24457896
883:: 3139.
687:13090739
679:24948369
596:Chang HY
389:Novartis
387:to form
371:founded
349:antigens
341:Novartis
222:Novartis
190:antibody
58:, Taiwan
1616:7097553
1454:9433396
1416:9062345
1153:6606681
885:Bibcode
860:Alt URL
467:(TWAS)
448:, 2004.
168:Chinese
91:therapy
75:(Ph.D.)
1662:. TWAS
1623:
1613:
1605:
1460:
1452:
1414:
1407:507895
1404:
1396:
1351:
1327:
1308:
1229:
1176:
1151:
1143:
1108:
1100:
1064:
1042:15 May
1016:
1006:
972:
913:
905:
853:15 May
685:
677:
488:Nature
385:Sandoz
335:; and
301:Career
287:T cell
202:asthma
198:Xolair
178::
176:pinyin
170::
135:, Inc.
107:Fields
84:Xolair
1458:S2CID
1106:S2CID
847:(PDF)
836:(PDF)
818:(PDF)
777:3 May
755:3 May
733:3 May
711:3 May
683:S2CID
469:Prize
373:Tanox
210:Tanox
133:Tanox
87:anti-
1621:PMID
1603:ISSN
1450:PMID
1412:PMID
1394:ISSN
1349:ISSN
1227:ISSN
1174:ISBN
1149:PMID
1141:ISSN
1098:ISSN
1044:2017
1014:PMID
1004:ISBN
970:PMID
911:PMID
903:ISSN
855:2017
779:2017
757:2017
735:2017
713:2017
675:PMID
355:and
220:and
35:Born
1611:PMC
1595:doi
1442:doi
1402:PMC
1386:doi
1133:doi
1090:doi
1086:192
996:doi
960:doi
956:348
893:doi
665:doi
661:135
628:."
615:."
602:."
587:."
576:."
563:."
550:."
537:."
524:."
511:."
485:."
312:IgE
295:MIT
214:IgE
172:張子文
89:IgE
27:張子文
1696::
1619:.
1609:.
1601:.
1591:24
1589:.
1585:.
1541:.
1456:.
1448:.
1438:62
1436:.
1410:.
1400:.
1392:.
1382:99
1380:.
1376:.
1347:.
1343:.
1275:.
1225:.
1221:.
1209:^
1147:.
1139:.
1129:65
1127:.
1104:.
1096:.
1084:.
1080:.
1034:.
1012:.
1002:.
982:^
968:.
949:.
937:^
909:.
901:.
891:.
879:.
875:.
838:.
703:.
681:.
673:.
659:.
655:.
498:"
261:,
253:,
174:;
117:,
113:,
54:,
43:)
1682:"
1669:.
1648:.
1627:.
1597::
1570:.
1527:.
1506:.
1485:.
1464:.
1444::
1418:.
1388::
1361:.
1290:.
1260:.
1239:.
1203:.
1182:.
1155:.
1135::
1112:.
1092::
1046:.
1020:.
998::
976:.
962::
917:.
895::
887::
881:5
857:.
802:.
781:.
759:.
737:.
715:.
689:.
667::
166:(
39:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.